AVBP ArriVent BioPharma Inc Aggregate Company Assets

Official company branding of ArriVent BioPharma (AVBP)

The market dynamics of ArriVent BioPharma, Inc (AVBP) demonstrate total assets at 332.13, confirming the potential for pricing power following the launch of a drug for the therapy of resistant forms of lung cancer. Resource growth is supported by intensive global testing of a new molecule within the R&D cycle, while the business implements ESG principles by optimizing water consumption and reagent disposal in its laboratories.

arrivent.com (AVBP) Aggregate Company Assets: for the period 02/21/2024 - 10/30/2026

Analytical breakdowns and data insights for company ArriVent BioPharma (AVBP)

- current price and projected stock value:
Quote Chart ArriVent BioPharma, Inc|AVBP - Price Target Chart
- market capitalization data:
Market Value ArriVent Corp|AVBP - Real Price to Acquire Entire Company
- book capitalization indicators:
Book Value per Share ArriVent BioPharma|AVBP - Company Book Value|Capitalization to Book Value Ratio arrivent.com|AVBP - Company Total Assets
- debt and solvency information:
Debt to Capital Ratio ArriVent BioPharma, Inc|AVBP - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient ArriVent BioPharma, Inc.|AVBP - Company Total Debt|Debt to Net Assets Ratio ArriVent Corp|AVBP - Company Long-Term Debts|Company Current Liabilities ArriVent BioPharma|Quick Ratio arrivent.com
- earnings and market multiples details:
AVBP - Company Net Income
Summary company analysis:ArriVent (AVBP)
Original product of ArriVent BioPharma, Inc.

Return on assets (ROA) dynamics allow for an assessment of resource efficiency, eliminating the risk of hidden business degradation when shares appear cheap on the surface. By analyzing total assets calculated reversely through ROA, an investor can determine the aggregate asset value of ArriVent BioPharma, Inc (AVBP), which is critical for valuing patents and the development potential of targeted lung cancer therapies.

Direct competitors

Total Asset Value of Company LTRN (Lantern Pharma)|Aggregate Company Assets bioAffinity Technologies Inc.|Aggregate Company Assets EFTR